Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis

(2015) Karen Dybkær et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of p53 enhances the function of the endoplasmic reticulum through activation of the IRE1α/XBP1 pathway

(2015) Takushi Namba et al.   Oncotarget

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

(2014) C. Y. Ok et al.   CLINICAL CANCER RESEARCH

Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression

(2014) Regina Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

The downregulation of PRDM1/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK/T-cell lymphoma, nasal type

(2014) Li Liang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Germinal center B cell maintenance and differentiation are controlled by distinct NF-κB transcription factor subunits

(2014) Nicole Heise et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Histone Deacetylase Inhibitors Upregulate B Cell microRNAs That Silence AID and Blimp-1 Expression for Epigenetic Modulation of Antibody and Autoantibody Responses

(2014) Clayton A. White et al.   JOURNAL OF IMMUNOLOGY

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program

(2013) Z. Y. Xu-Monette et al.   BLOOD

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

(2013) S. Hu et al.   BLOOD

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

(2013) Alexandar Tzankov et al.   MODERN PATHOLOGY

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

(2012) C. Visco et al.   HAEMATOLOGICA

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

(2012) C Visco et al.   LEUKEMIA

Epigenetic Down-Regulation of the Tumor Suppressor Gene PRDM1/Blimp-1 in Diffuse Large B Cell Lymphomas

(2010) Kui Nie et al.   AMERICAN JOURNAL OF PATHOLOGY

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

(2010) Dinis Pedro Calado et al.   CANCER CELL

BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma

(2010) Jonathan Mandelbaum et al.   CANCER CELL

Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype

(2010) S. Montes-Moreno et al.   HAEMATOLOGICA

Follicular dendritic cell-induced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas

(2010) J Lin et al.   LEUKEMIA

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation

(2010) Shane Crotty et al.   NATURE IMMUNOLOGY

Aggressive Lymphomas

(2010) Georg Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myc proteins as therapeutic targets

(2010) W C Gustafson et al.   ONCOGENE

Regulation and Functions of Blimp-1 in T and B Lymphocytes

(2008) Gislâine Martins et al.   Annual Review of Immunology